PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...

TOKYO and NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the ...

ImmunityBio Executive Chairman Patrick Soon-Shiong criticized the FDA for applying tougher approval standards to Anktiva than ...

Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

Keytruda shows consistent efficacy and safety in advanced bladder carcinoma patients ineligible for platinum-based chemotherapy, with varying objective response rates and survival metrics across ...

The MarketWatch News Department was not involved in the creation of this content. -- PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve ...

When bladder cancer invades nearby muscle, total removal of the organ is the standard of care A new trial finds that post-op use of the immunotherapy drug Keytruda can double the time these patients ...

TOKYO and NEW YORK, Dec. 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be ...